Somatropin (HGH)

Somatropin is the International Nonproprietary Name (INN) for recombinant human growth hormone produced as a 191-amino-acid protein with a sequence identical to native pituitary GH. 'HGH' is the informal umbrella term for human growth hormone in general — so somatropin *is* HGH, specifically the FDA-approved pharmaceutical form. Older marketing terms like 'HGH 191AA' emphasize that the molecule is the full-length natural sequence (as opposed to Genentech's discontinued Protropin/somatrem, which had an extra N-terminal methionine). All currently FDA-approved branded GH products — Humatrope, Genotropin, Norditropin, Omnitrope, Saizen, Zomacton, Serostim, Skytrofa, Ngenla, Sogroya — are somatropin or closely related modifications of it.

Not for FDA-approved indications with a valid prescription. HGH (somatropin) is legal and widely used for pediatric growth hormone deficiency, adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, HIV-associated wasting, and several other conditions. Off-label distribution is a different matter. 21 U.S.C. §333(e) is a federal statute written specifically for HGH that makes distribution for any use other than an FDA-approved indication a federal crime — up to 5 years imprisonment (10 if distributed to a minor). This applies to physicians prescribing for bodybuilding or anti-aging, to the 'research chemical' vendor industry, and to compounding pharmacies distributing HGH for non-approved uses.

No — the clinical evidence does not support this use. The definitive meta-analysis by Liu et al. in Annals of Internal Medicine (2007) pooled 18 randomized controlled trials of GH in healthy older adults and found only small changes in body composition (~2.1 kg more lean mass, ~2.1 kg less fat) accompanied by substantially higher rates of edema, arthralgias, carpal tunnel syndrome, and impaired fasting glucose. No improvement in functional measures, cognition, cardiovascular risk, or longevity was demonstrated. The authors explicitly concluded GH cannot be recommended as an anti-aging therapy. The original 'Rudman 1990' NEJM paper that launched the anti-aging HGH industry had only 12 treated patients over 6 months and did not measure the harms — it has been widely cited as having been over-interpreted by the commercial anti-aging field.

For the classical daily-injection products (Humatrope, Genotropin, Norditropin, Omnitrope, Saizen, Zomacton), the active ingredient is the same 191-amino-acid somatropin molecule. Differences are in formulation (preservative, diluent, delivery device), pen design, storage requirements, and price. Clinical efficacy is equivalent at equivalent doses. Skytrofa (lonapegsomatropin, approved 2021) is different — it is a prodrug that covalently tethers somatropin to a PEG carrier and releases unmodified somatropin over a week, enabling weekly rather than daily dosing. The heiGHt Phase 3 trial (Thornton 2021) demonstrated non-inferior and modestly superior height velocity vs daily somatropin in treatment-naïve children. Ngenla (somatrogon, 2023) and Sogroya (somapacitan, 2023 adult) are separate long-acting molecules and have their own encyclopedia entries.

Somatropin is among the most expensive chronic medications in routine use. US list prices for branded somatropin run roughly $7,000–$35,000 per year for an adult on replacement, depending on brand, dose, and formulation. Pediatric costs can exceed $40,000/year at higher weight-based doses. Long-acting weekly formulations (Skytrofa, Ngenla, Sogroya) typically price at a premium to daily somatropin. Omnitrope was the first EMA-approved biosimilar of any protein drug (2006) and offers meaningful savings in many markets. Insurance coverage for adult GHD is often restrictive — many plans require documented severe deficiency on two stimulation tests plus pituitary imaging evidence.

At therapeutic replacement doses the profile is well-characterized. Most common is fluid retention — peripheral edema, carpal tunnel symptoms, and arthralgias — especially during the first weeks of adult replacement and often resolving with dose reduction. Impaired fasting glucose develops in a subset; dose adjustment plus standard diabetes screening manages this. Pediatric-specific concerns include benign intracranial hypertension (routine fundoscopy during titration), slipped capital femoral epiphysis (hip/knee pain triggers evaluation), and scoliosis progression. The 24,232-patient SAGhE cohort followed European children into adulthood and found no increase in all-cause mortality for patients with low-risk indications (isolated GHD, idiopathic short stature) at 25 years.

The answer depends substantially on the patient population. For healthy adults used off-label: the theoretical concern is real (IGF-1 is mitogenic, and population studies have found associations between serum IGF-1 and several cancers), but there is no prospective RCT evidence quantifying this risk at off-label doses because such trials would be unethical. For pediatric replacement: SAGhE followed 24,232 European children through adulthood and found no increase in cancer mortality for low-risk indications. Patients with pre-existing malignancies, cancer predisposition syndromes (Fanconi anemia, Bloom syndrome), or prior radiation therapy represent a higher-risk population where individualized risk-benefit assessment is required. Active malignancy is an absolute contraindication across all FDA labels.

Depends on the indication. Pediatric growth: first-year height velocity improvement is measurable within 6 months and is the standard early efficacy check. Turner syndrome: adult-height gain accrues over 8–12 years of treatment. Adult GHD replacement: body-composition changes (reduced visceral fat, increased lean mass) are measurable at 3–6 months, peak around 12 months, and sustain with continued treatment. Quality-of-life improvements follow a similar timeline. Fluid-retention side effects appear within days of initiation and typically resolve or attenuate within 2–8 weeks.

Somatropin *is* growth hormone — the full 22 kDa protein that acts directly on the GH receptor. CJC-1295 and ipamorelin are growth hormone secretagogues (GHS) — smaller peptides that act upstream on the pituitary to increase endogenous GH release. Mechanistically they are fundamentally different: somatropin bypasses the pituitary entirely, while GHS drive the patient's own pulsatile GH secretion. Clinically they differ in regulatory status (somatropin is FDA-approved for defined indications; CJC-1295 and ipamorelin are not FDA-approved for any human use), cost (somatropin is vastly more expensive), and side-effect profile (GHS produce lower peak IGF-1 exposure and are less likely to cause edema/carpal tunnel). For documented GH deficiency, somatropin is the appropriate therapy; GHS are primarily investigational or grey-market.

Three factors. First, GH has a reputation — earned from the Rudman 1990 study and amplified by the anti-aging industry — for producing visible body-composition changes (leaner appearance, reduced abdominal fat). Second, unlike anabolic steroids, HGH does not produce classical androgen-like 'positive doping' tests and is difficult to detect in standard screening (the IGF-1/P-III-NP test used by WADA has meaningful false-negative rates). Third, prescription costs are high enough that a substantial grey market exists at intermediate prices. The combination prompted Congress to write 21 U.S.C. §333(e) — the only FDA-approved protein drug with its own criminal statute for off-label distribution — and it is why the DEA periodically targets compounding pharmacies and internet 'peptide vendors' selling 'research chemical' HGH.